Sanuwave Health (SNWV) risk factors
Item 1A of every Sanuwave Health, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors33 risks5 new6 dropped6 reworded
SANUWAVE added internal control material weakness risks and disclosed a $44.2 million NOL expiration from ownership changes. The company highlighted debt refinancing, net income of $11.8 million, and positive operating income for 2025. Reimbursement changes for wound care products like skin substitutes could indirectly reduce demand for the UltraMIST system.
Filed Mar 26, 2026 - FY2024 10-K risk factors34 risks
The company relies heavily on ongoing equity and debt financing to fund its continuous negative operating cash flows. Regulatory compliance with the FDA, healthcare laws, and extensive intellectual property protection dictate its commercial viability.
Filed Mar 20, 2025